Hypothalamic pituitary adrenal axis hormone changes during IL-17A inhibition with secukinumab in patients with psoriasis
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 282(2025) vom: 18. Okt., Seite 110611 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , |
| Format: | Article en ligne |
| Langue: | English |
| Publié: |
2025
|
| Accès à la collection: | Clinical immunology (Orlando, Fla.) |
| Sujets: | Journal Article Hypothalamic pituitary adrenal axis IL-17 a inhibition Psoriasis Secukinumab |
| Résumé: | Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved. PURPOSE: Secukinumab, an interleukin-17 A (IL-17 A) inhibitor, is an approved treatment for psoriasis, but effects on the hypothalamic pituitary adrenal (HPA) axis are unknown METHODS: In a 16-week randomized controlled trial, 105 patients with psoriasis received secukinumab at either 300 or 75 mg. Plasma levels of IL-17 A, cortisol, adrenocorticotropic hormone, prolactin, dehydroepiandrosterone and perceived stress using Perceived Stress Scale (PSS-10) were measured at baseline and every four weeks. Treatment response was assessed using Psoriasis Area and Severity Index (PASI) RESULTS: Both dosage groups showed significant increases in IL-17 A and cortisol, with no differences between groups. Cortisol increased by approximately 33 %, indicating activation of HPA axis. Changes in cortisol did not correlate with PASI. PSS-10 inversely correlated with cortisol at baseline, and shifted positive during follow-up CONCLUSION: Secukinumab treatment in psoriasis is accompanied by HPA axis activation. Further studies are needed to determine the duration, mechanisms, and magnitude of this activation |
|---|---|
| Description: | Date Revised 22.10.2025 published: Print-Electronic Citation Status Publisher |
| ISSN: | 1521-7035 |
| DOI: | 10.1016/j.clim.2025.110611 |